• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Tetra Bio-Pharma's Corporate Update & Annual Mtg. Results

July 11, 2017


This afternoon, Tetra Bio-Pharma (CSE:TBP)(OTC:TBPMF) announced the voting results from the company's recent annual shareholders' meeting as well as some recent operational developments. Here's the highlights...


Voting Results 


Shareholders' of the company elected André Rancourt, André D. Audet, Robert Brouillette and Dr. W.M. (Bill) Cheliak to Tetra Bio-Pharma's board. They also voted to appoint McGovern, Hurley, Cunningham, LLP as the company's auditor, to allow the board to determine the compensation of the auditors and to amend the stock option plan from a fixed to a rolling plan. 


Corporate Highlights


  • Tetra is believed to be the only pharmaceutical company to have conducted clinical trials for smoked marijuana.

  • Management believes the company is financially sound, and that they have enough cash to pay for the phase three clinical trials of PPP001 (their dried cannabis prescription drug being developed for advanced cancer pain) that will cost ~$1.2 million CAD. 

  • The company intends to start these phase three trials in the fourth quarter with approximately 600 participants. 

  • Tetra Bio-Pharma is focused on seeking out international commercialization partnerships, initial interest has been shown from companies located in the US, Mexico, Ireland, Brazil and Germany

  • Forecasted initial demand for PPP001 (using Aphria's ACMPR license, as opposed to the pharmaceutical route) is higher than the company expected. Tetra is working to ramp up manufacturing capabilities to meet this demand. 

  • The company is considering launching PPP001 using Aphria's ACMPR license by the end of the summer. 

  • Tetra Bio-Pharma is looking at starting phase two clinical trials for PPP002 - Dronabinol XL (a sustained release synthetic THC buccally absorbed wafer that is initially being studied in patients with chronic pain and chemotherapy associated nausea and vomiting) this month. 




The Daily Marijuana Observer is working on a marijuana stock profile for Tetra Bio-Pharma so check back soon, or subscribe to their free email newsletter to find out when it becomes available. 
If you haven't already, be sure to connect with The Daily Marijuana Observer on Facebook, Twitter and Instagram.




Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.

Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.